What Is the Status of the Dupixent Lawsuit in Iowa?

Super Lawyers® 2014–2024(888) 348-2735

Dupixent — CTCL Litigation

The Dupixent Litigation, Explained

Federal cases are consolidated in MDL 3180, most cases are in their earliest stages, and no settlement exists. Here is what is publicly known.

ACTIVE LITIGATION — NO SETTLEMENT. MDL 3180 underway · deadlines vary by state.

Marin & Murphy is not licensed in Iowa; details below.

Partners

Stefanie A. Murphy & Matthew T. Marin

Super Lawyers® honorees · members of the American Association for Justice · concentrating in personal injury and mass-tort litigation.

No settlement has been reached in the Dupixent litigation, and most cases are in their earliest stages. Every case must be proven on its own facts. Whether any patient has a claim depends on the facts and the law of their state. The information below covers the litigation itself.

Marin & Murphy Law Firm is not licensed in Iowa; details below.

The Dupixent CTCL Litigation: Where Things Stand

Dupixent (dupilumab), a Sanofi and Regeneron prescription biologic prescribed to patients in Iowa and nationwide, has been FDA-approved since March 2017 and now carries nine indications, including atopic dermatitis, asthma, and COPD. The order that matters for Iowa filings came in June 2026: the Judicial Panel on Multidistrict Litigation centralized the pending federal cases as MDL 3180 in the United States District Court for the District of New Jersey, before Judge Zahid N. Quraishi. The complaints in the consolidated Dupixent lawsuit allege that the drug is associated with an increased risk of cutaneous T-cell lymphoma (CTCL) and that the manufacturers failed to warn patients and doctors. Thirty-eight pending cases were on the MDL docket — the same proceeding a case from Iowa would join — as of October 1, 2026; the MDL 3180 tracker keeps the current count and its method. For Iowa claimants as for all others, no court has ruled on the merits and no settlement exists.

The Allegations — and Their Limits

The allegation — in Iowa as anywhere else — is an association, not an adjudicated fact. Published studies report a statistical association between dupilumab and CTCL — an association the study authors themselves note does not establish causation — and the FDA has identified a potential safety signal for CTCL that it is still evaluating. The Dupixent label dispensed in Iowa, as everywhere, carries no lymphoma or malignancy warning today. The FDA adverse event reports connected to this question are agency reports, not verified causes, and the courts have decided nothing on the merits — in Iowa or anywhere else.

Is Anyone From Iowa Already in the Dupixent Litigation?

Possibly, but the public record does not yet let us say so responsibly. All federal Dupixent CTCL cases are consolidated in MDL 3180 in the District of New Jersey, and the MDL’s member-case complaints are mostly not in the free public record; a case’s original filing court also does not establish where the plaintiff lives. This page therefore reports the litigation’s overall posture through the MDL 3180 tracker rather than an unverified Iowa figure, and it will describe an Iowa resident’s case when a publicly available complaint documents one.

Who Falls Within the Filed Cases?

People in the consolidated cases — a group any qualifying claimant from Iowa would join — used Dupixent and received a diagnosis of cutaneous T-cell lymphoma or a related T-cell subtype during or after use. No minimum duration of Dupixent use is required — in Iowa or anywhere — and the group includes estate claims, brought under state wrongful-death and survival statutes, for patients who have died. Whether any individual’s circumstances resemble the filed cases is a question of medical records and state law, not of headlines — and for an Iowa resident, it is a question for an attorney licensed in Iowa.

Iowa’s Federal Courts and the Path to MDL 3180

Iowa is served by two federal district courts: the United States District Court for the Northern District of Iowa and the United States District Court for the Southern District of Iowa. A Dupixent CTCL lawsuit filed there does not proceed alone: the Judicial Panel on Multidistrict Litigation has centralized these cases as MDL 3180 before Judge Zahid N. Quraishi in the United States District Court for the District of New Jersey, so an Iowa case is transferred to the MDL for coordinated pretrial proceedings — or, where the MDL court’s case-management orders permit, filed in the District of New Jersey directly. The destination is the same consolidated proceeding either way; a claim from Iowa stays an individual claim, because an MDL is not a class action.

Filing Deadlines Under Iowa Law

Iowa’s general statute of limitations for personal-injury claims is two years under Iowa Code § 614.1(2). Iowa applies a discovery rule: the period runs when the plaintiff becomes aware of a problem sufficient to require a diligent investigation into its cause. How a limitations period applies to any specific CTCL diagnosis depends on the dates in the medical records, the legal theory pleaded, and Iowa tolling and accrual doctrine. An attorney licensed in Iowa can evaluate whether a claim is timely.

A wrongful-death claim carries a two-year period that begins at death (Iowa Code § 614.1(2)), brought by the personal representative.

How Common Is CTCL in Iowa?

Iowa is home to about 3.2 million people (U.S. Census Bureau, 2024 estimate). Cutaneous T-cell lymphoma is rare — roughly 8.55 new cases per million person-years (SEER) — which works out to on the order of 25 new CTCL diagnoses across Iowa in a typical year. Because the disease is so rare, no statistic here answers an individual question; in Iowa, a single claim turns on medical records read against state law.

About Marin & Murphy Law Firm and Iowa

Marin & Murphy Law Firm is a personal-injury and mass-tort law firm; its attorneys’ individual admissions are listed at the bottom of this page, and this page is published as litigation information. Marin & Murphy Law Firm is not licensed in Iowa. The firm does not accept Iowa legal matters; inquiries from Iowa residents are referred to attorneys licensed in Iowa. Some matters may be referred to other lawyers. An attorney licensed in Iowa can evaluate whether a claim is timely and how Iowa law applies to a particular diagnosis.

Iowa Dupixent Litigation FAQs